Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0002 USD | 0.00% | +19,900.00% | -83.33% |
04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
03-08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
Sales 2021 | 3.6 286.53 | Sales 2022 | 2.51 200.37 | Capitalization | 14.29M 1.14B |
---|---|---|---|---|---|
Net income 2021 | -237M -18.89B | Net income 2022 | -70M -5.58B | EV / Sales 2021 | 53,517,059 x |
Net cash position 2021 | 45.01M 3.59B | Net cash position 2022 | 10.16M 809M | EV / Sales 2022 | 1,644,636 x |
P/E ratio 2021 |
-0.92
x | P/E ratio 2022 |
-0.15
x | Employees | 6 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.65% |
3 months | +100.00% | ||
6 months | -90.00% | ||
Current year | -83.33% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Ronald Barliant
BRD | Director/Board Member | 78 | 06/01/16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 0.0002 | 0.00% | 191,427 |
Delayed Quote OTC Markets, April 29, 2024 at 02:31 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-83.33% | 23.82K | |
-3.45% | 87.17B | |
+1.97% | 40.1B | |
+57.86% | 25.12B | |
-14.82% | 15.59B | |
-8.82% | 12B | |
-16.29% | 11.8B | |
-41.58% | 11.8B | |
+6.89% | 8.81B | |
-10.53% | 8.24B |
- Stock Market
- Equities
- HGENQ Stock